H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), ...

Investment analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Enanta Pharmaceuticals in a report released on Tuesday, February 11th. HC Wainwright analyst E. Arce now expects that ...

Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share estimates for shares of Sensus Healthcare in a research note issued on Monday, February 10th. HC Wainwright analyst Y. Chen now ...

Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...

H.C. Wainwright analyst Patrick Trucchio revised the price target on Compass Pathways (NASDAQ:CMPS) stock, reducing it to $45 ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...

The aggregate gross proceeds to the Company from the offering were approximately $1,050,000, before deducting the placement agent fees and other offering expenses payable by the Company. The Company ...